Search PubMed⌕ Search

Biomedical subjects

N Mitani

Publications and source records attributed to N Mitani.

At least 37 records · Page 2Linked to original sources
PubMed1989

[Primary lung cancer of the right middle lobe].

During the period from 1973 to 1986, 230 patients with lung cancer were operated on at our Surgical Clinic of Kagoshima University Hospital. There were fourteen patients (6.1%) with lung cancer in the right middle lobe. There were 13 male and 1 female patients. The histological types were adenocarcinoma (10), squamous cell carcinoma (4). Five-year survival rate of 14 patients was 34.9%. Statistically, it was similar to that of the patients with lung cancer in the other lobes. As concerns with the histological type of lung cancer in the right middle lobe, the case of squamous cell carcinoma revealed poorer prognosis than those of adenocarcinoma, because there were many cases of advanced cancer in the former case.

Adenocarcinoma↗
PubMed1989

[A resected case of triple cancer in the uterus, lung and thyroid].

A 62 year-old woman was admitted to our clinic for the treatment of lung cancer. Right middle and lower lobectomy was performed. Histological diagnosis was well differentiated adenocarcinoma in the right lower lobe (yp-T2N1M0, stage II). Forty-seven months before the pulmonary resection (at the age of 57 year-old), she had undergone hysterectomy for squamous cell carcinoma of the uterus (carcinoma in situ). Forty-three months after the pulmonary resection (at the age of 65 year-old), two minute thyroid cancer were resected. Twenty-one resected cases of triple cancer including lung cancer have been reported in Japanese literature.

Adenocarcinoma↗
PubMed1982

Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans.

The absorption, excretion, and metabolism of a single oral dose of suxibuzone, a new nonsteroidal anti-inflammatory agent, in healthy male volunteers were compared with those of phenylbutazone. After oral administration of either suxibuzone or phenylbutazone, phenylbutazone, oxyphenbutazone, and gamma-hydroxyphenylbutazone were found in the plasma; phenylbutazone was the main metabolite of suxibuzone and phenylbutazone. In the urine, p-gamma-dihydroxyphenylbutazone and several glucuronide conjugates also were found. Spectrometric and/or enzymatic analysis showed that these glucuronide conjugates were suxibuzone glucuronide, 4-hydroxymethylphenylbutazone glucuronide, 4-hydroxymethyloxyphenbutazone glucuronide, oxyphenbutazone glucuronide, and phenylbutazone glucuronides (two types: O-glucuronide and C-4-glucuroxide) after suxibuzone administration, and oxyphenbutazone glucuronide and phenylbutazone glucuronide after phenylbutazone administration. The conjugates specific to suxibuzone administration, suxibuzone glucuronide, 4-hydroxymethylphenylbutazone glucuronide, and 4-hydroxymethyloxyphenbutazone glucuronide, were excreted in the first 6 hr urine. These findings and the pharmacokinetics of these metabolites in the plasma and urine show that suxibuzone is a prodrug of phenylbutazone.

Adult↗